{"id":"W4212861966","doi":"10.1200/jco.2022.40.6_suppl.tps404","title":"Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenvatinib; Clear cell renal cell carcinoma; Pembrolizumab; Internal medicine; Renal cell carcinoma; Oncology; Phases of clinical research; Clinical trial; Kidney cancer; Tolerability; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002679458,0.001867842,0.001793155,0.0005020191,0.0005492001,0.001111279,0.001305772,0.001384115,0.009823611],"category_scores_gemma":[0.0009198192,0.0007863205,0.001326508,0.0006133035,0.0008243219,0.001021945,0.0005601736,0.002918002,0.002333571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001224742,"about_ca_system_score_gemma":0.002111244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001688408,"about_ca_topic_score_gemma":0.004040126,"domain_scores_codex":[0.999357,0.0003448052,0.00002254684,0.00008946088,0.00006973229,0.0001164512],"domain_scores_gemma":[0.999355,0.0000662509,0.0001193268,0.00006048413,0.00004319239,0.0003556359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7406362,0.07312191,0.01742081,0.001062849,0.001945928,0.0003424869,0.0002909715,0.002015227,0.027778,0.0005623315,0.02163423,0.1131891],"study_design_scores_gemma":[0.7787069,0.1941957,0.01674965,0.00004814477,0.0005236465,0.0003281174,0.00005917945,0.001168786,0.001485295,0.0002937567,0.006413658,0.00002715916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721496,0.004102433,0.0009746053,0.001465808,0.0002627047,0.008290205,0.00699967,0.0002769568,0.005478117],"genre_scores_gemma":[0.9579769,0.002994125,0.0040066,0.003007054,0.0003289293,0.0104895,0.01354035,0.0001117595,0.00754481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009823611,"threshold_uncertainty_score":0.03286326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06351321590298831,"score_gpt":0.3829250473632752,"score_spread":0.3194118314602868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}